Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.63 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.63 |
| ▸ | F7 | P08709 | 1/20 | 0.61 |
| ▸ | F3 | P13726 | 1/20 | 0.61 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.61 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.61 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.61 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.61 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacin SCHEMBL29778212 | 1.00 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL27516641 | 0.98 | ALDH1A1 (0.61) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL987479 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL587526 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL517582 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL25269786 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL10357700 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL23780930 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL1943861 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL3498987 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | claimed |
| US-20250250476-A1 | SEALING GEL WITH DELAYED GELATION FOR WELL CEMENTATION, PREPARATION METHOD, AND APPLICATION | CHINA UNIVERSITY OF PETROLEUM (EAST CHINA) (CN) | 2025-08-07 | — | — | US | claimed |
| US-12378462-B1 | Sealing gel with delayed gelation for well cementation, preparation method, and application | CHINA UNIVERSITY OF PETROLEUM (EAST CHINA) (CN) | 2025-08-05 | — | — | US | claimed |
| WO-2025137656-A1 | PLANT-BASED COMPOSITIONS AND METHODS FOR HORMONE SIGNALING, BLOOD GLUCOSE CONTROL, APPETITE CONTROL, AND WEIGHT MANAGEMENT | Alpine Biotech, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250205300-A1 | PLANT-BASED COMPOSITIONS AND METHODS FOR HORMONE SIGNALING, BLOOD GLUCOSE CONTROL, APPETITE CONTROL, AND WEIGHT MANAGEMENT | Alpine Biotech, LLC (US) | 2025-06-26 | — | — | US | claimed |
| CN-119791203-A | Preparation method, device and application of alkaline ionic liquid for animals | 江苏大方生物工程有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119769643-A | Solid-state fermentation feed additive and preparation method thereof | 南城华农恒青农牧有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119453477-A | Composition for accelerating fat catabolism, preparation method and application | 广东贝塔生物科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-115974099-B | Three-dimensional titanium phosphate framework co-top oxygen type lithium ion sieve and preparation method thereof | 南京工业大学 | 2024-11-12 | — | — | CN | claimed |
| CN-118925723-A | Silver catalyst and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-11-12 | — | — | CN | claimed |
| WO-2002036202-A2 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF INSULIN SENSITIVITY, REDUCTION OF HYPERGLYCEMIA, AND REDUCTION OF HYPERCHOLESTEROLEMIA WITH CHROMIUM COMPLEXES AND ALPHA LIPOIC ACID | NUTRITION 21, INC. (US) | 2002-05-10 | — | — | WO | claimed |
| WO-2002036127-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME WITH CHROMIUM COMPLEXES | NUTRITION 21, INC. (US) | 2002-05-10 | — | — | WO | claimed |
| WO-2002024180-A2 | CHROMIUM CONTAINING COMPOSITIONS FOR THE TREATMENT OF DIABETES, THE REDUCTION OF BODY FAT, IMPROVEMENT OF INSULIN SENSITIVITY AND REDUCTION OF HYPERGLYCEMIA AND HYPERCHOLESTEREMIA | NUTRITION 21, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| EP-1158972-A1 | TREATMENT OF HYPERTENSION WITH COMPOUNDS THAT INHIBIT THE DESTRUCTION OF ENKEPHALINS OR ENDORPHINS | Ehrenpreis, Seymour (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2001026642-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROBEHAVIORAL DISORDERS | BECHTHOLD JOYCE CORINNE (US) | 2001-04-19 | — | — | WO | claimed |
| US-6132724-A | Allelic polygene diagnosis of reward deficiency syndrome and treatment | CITY OF HOPE NATIONAL MEDICAL CENTER (US) | 2000-10-17 | — | — | US | claimed |
| WO-2000041686-A1 | TREATMENT OF HYPERTENSION WITH COMPOUNDS THAT INHIBIT THE DESTRUCTION OF ENKEPHALINS OR ENDORPHINS | EHRENPREIS SEYMOUR (US) | 2000-07-20 | — | — | WO | claimed |
| EP-0979092-A2 | ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT | Kenneth Blum, Inc. (US) | 2000-02-16 | — | — | EP | claimed |
| WO-1998048785-A9 | ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT | KENNETH BLUM INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1998048785-A2 | ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT | KENNETH BLUM, INC. (US) | 1998-11-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | ALDH1A1 4359/4885GAA 139/4885APP 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.